Opinion|Videos|January 7, 2025
HPV Self-Collection Screening: What OB/GYNs Should Know
Author(s)Kameelah Phillips, MD, FACOG, NCMP
The panelist discusses the cautions around recent FDA approvals on human papillomavirus (HPV) self-collection, including limitations and sensitivity while emphasizing the importance of patients continuing to see their OB/GYN regularly.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the benefits and limitations of HPV self-collection, and who is it particularly designed for?
- How does the sensitivity of HPV self-collection compare with traditional collection methods?
- How can education about HPV and HPV screening influence screening rates?
Advertisement
Related to this article
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
4
Matthew Nudy, MD, on estrogen and the cardiovascular system
5